CoChat
Sign Up
Cited by 19Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Decreased Expression of Sulfatase 2 in the Brains of Alzheimer’s Disease Patients: Implications for Regulation of Neuronal Cell Signaling

Open access
Roberts, Rosebud O., Kang, Yoo Na, Hu, Chunling, Moser, Catherine D., Wang, Shaoqing, Moore, Michael J., Graham, Rondell P., Lai, Jin-Ping +2 more·2017·Journal of Alzheimer's Disease Reports
DOI 10.3233/adr-170028PMC PMC6052874
Open this paper in CoChat — free account

Abstract

Background: The human sulfatase 1 (SULF1) and sulfatase 2 (SULF2) genes modulate cell signaling and homeostasis in many tissues. Gene expression analyses have implicated SULF2 in disease pathogenesis, including Alzheimer’s disease (AD), but changes in brain SULF2 expression have not been directly established. Objective: To investigate the expression of SULF1 and SULF2 in brain tissues from AD cases and cognitively normal controls. Methods: Autopsy tissue from AD cases ( n = 20) and age-and gender-matched cognitively normal controls ( n = 20) were identified from the Mayo Clinic Alzheimer’s Disease Patient Registry neuropathology database. Tissue slides were stained for SULF1 and SULF2 protein expression in the hippocampus and frontal lobe and an expression score computed from the proportion of cells stained and the intensity of staining (range 0 [no expression] to 9 [marked expression]). Results: SULF2 expression was reduced in AD cases. Compared to cognitively normal controls, SULF2 expression in AD cases was significantly decreased in the hippocampal Cornu Ammonis (CA) (mean score of 6.5 in cases versus 8.3 in controls; p = 0.003), in the gray matter of the parahippocampal gyrus (5.6 in cases versus 7.6 in controls; p = 0.003), and in the frontal lobe gray matter (5.4 in cases versus 7.4 in controls; p = 0.002). There was no difference in SULF1 expression in the hippocampus or frontal lobe of AD cases and controls. As expected there were no differences in SULF1 or SULF2 expression in white matter in AD cases compared to cognitively normal controls. Conclusion: Decreased SULF2 in specific regions of the brain occurs in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/adr-170028

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 62

  1. [1]Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement 12, 459– 509. 27570871
  2. [2]Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778– 1783. 23390181 PMC3719424
  3. [3]Murphy SL, Kochanek KD, Xu JQ, Heron M (2015) Deaths: Final data for 2012. National Vital Statistics Reports; vol 63 no 9. National Center for Health Statistics, Hyattsville, MD. 26759855
  4. [4]Kerchner GA, Deutsch GK, Zeineh M, Dougherty RF, Saranathan M, Rutt BK (2012) Hippocampal CA1 apical neuropil atrophy and memory performance in Alzheimer’s disease. Neuroimage 63, 194– 202. 22766164 PMC3677969
  5. [5]Macdonald KE, Bartlett JW, Leung KK, Ourselin S, Barnes J (2013) The value of hippocampal and temporal horn volumes and rates of change in predicting future conversion to AD. Alzheimer Dis Assoc Disord 27, 168– 173. 22760170 PMC4154837
  6. [6]Gemma C, Bachstetter AD, Cole MJ, Fister M, Hudson C, Bickford PC (2007) Blockade of caspase-1 increases neurogenesis in the aged hippocampus. Eur J Neurosci 26, 2795– 2803. 18001276
  7. [7]Liu P, Gupta N, Jing Y, Zhang H (2008) Age-related changes in polyamines in memory-associated brain structures in rats. Neuroscience 155, 789– 796. 18621105
  8. [8]Kempermann G (2008) The neurogenic reserve hypothesis: What is adult hippocampal neurogenesis good for? Trends Neurosci 31, 163– 169. 18329110
  9. [9]Revest JM, Dupret D, Koehl M, Funk-Reiter C, Grosjean N, Piazza PV, Abrous DN (2009) Adult hippocampal neurogenesis is involved in anxiety-related behaviors. Mol Psychiatry 14, 959– 967. 19255582
  10. [10]Lee SH, Han JH, Choi JH, Huh EY, Kwon YK, Kaang BK (2003) The effect of brain-derived neurotrophic factor on neuritogenesis and synaptic plasticity in Aplysia neurons and the hippocampal cell line HiB5. Mol Cells 15, 233– 239. 12803487
  11. [11]Sebollela A, Freitas-Correa L, Oliveira FF, Mendes CT, Wasilewska-Sampaio AP, Camacho-Pereira J, Galina A, Brentani H, Passetti F, De Felice FG, Dias-Neto E, Ferreira ST (2010) Expression profile of rat hippocampal neurons treated with the neuroprotective compound 2,4-dinitrophenol: Up-regulation of cAMP signaling genes. Neurotox Res 18, 112– 123. 19949915
  12. [12]Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M (2008) Extracellular matrix: A matter of life and death. Connect Tissue Res 49, 203– 206. 18661343
  13. [13]Reuss B, von Bohlen und Halbach O (2003) Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 313, 139– 157. 12845521
  14. [14]Gomez-Palacio Schjetnan A, Escobar-Rodriguez ML (2007) Memory coding and retention: Brain-derived neurotrophic factor (BDNF) in synaptic plasticity. Rev Neurol 45, 409– 417. 17918107
  15. [15]Sandwall E, O’Callaghan P, Zhang X, Lindahl U, Lannfelt L, Li JP (2010) Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology 20, 533– 541. 20053627
  16. [16]Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T (2007) The heparanome–the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol 129, 290– 307. 17337080
  17. [17]Guimond S, Turner K, Kita M, Ford-Perriss M, Turnbull J (2001) Dynamic biosynthesis of heparan sulphate sequences in developing mouse brain: Aotential regulatory mechanism during development. Biochem Soc Trans 29, 177– 181. 11356149
  18. [18]Ford-Perriss M, Guimond SE, Greferath U, Kita M, Grobe K, Habuchi H, Kimata K, Esko JD, Murphy M, Turnbull JE (2002) Variant heparan sulfates synthesized in developing mouse brain differentially regulate FGF signaling. Glycobiology 12, 721– 727. 12460940
  19. [19]Scholefield Z, Yates EA, Wayne G, Amour A, McDowell W, Turnbull JE (2003) Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer’s beta-secretase. J Cell Biol 163, 97– 107. 14530380 PMC2173449
  20. [20]Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP Jr. (2004) QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci U S A 101, 4833– 4838. 15051888 PMC387334
  21. [21]Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277, 49175– 49185. 12368295 PMC2779716
  22. [22]Lai JP, Thompson JR, Sandhu DS, Roberts LR (2008) Heparin-degrading sulfatases in hepatocellular carcinoma: Roles in pathogenesis and therapy targets. Future Oncol 4, 803– 814. 19086847 PMC3042146
  23. [23]Hammond E, Khurana A, Shridhar V, Dredge K (2014) The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 4, 195. 25105093 PMC4109498
  24. [24]Yang JD, Sun Z, Hu C, Lai J, Dove R, Nakamura I, Lee JS, Thorgeirsson SS, Kang KJ, Chu IS, Roberts LR (2011) Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer 50, 122– 135. 21104785 PMC3253341
  25. [25]Dhanasekaran R, Nakamura I, Hu C, Chen G, Oseini AM, Seven ES, Miamen AG, Moser CD, Zhou W, van Kuppevelt TH, van Deursen JM, Mounajjed T, Fernandez-Zapico ME, Roberts LR (2015) Activation of the transforming growth factor-beta/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma. Hepatology 61, 1269– 1283. 25503294 PMC4376661
  26. [26]Nagamine S, Koike S, Keino-Masu K, Masu M (2005) Expression of a heparan sulfate remodeling enzyme, heparan sulfate 6-O-endosulfatase sulfatase FP2, in the rat nervous system. Brain Res Dev Brain Res 159, 135– 143. 16139897
  27. [27]Higginson JR, Thompson SM, Santos-Silva A, Guimond SE, Turnbull JE, Barnett SC (2012) Differential sulfation remodelling of heparan sulfate by extracellular 6-O-sulfatases regulates fibroblast growth factor-induced boundary formation by glial cells: Implications for glial cell transplantation. J Neurosci 32, 15902– 15912. 23136428 PMC3808811
  28. [28]Ratzka A, Mundlos S, Vortkamp A (2010) Expression patterns of sulfatase genes in the developing mouse embryo. Dev Dyn 239, 1779– 1788. 20503373
  29. [29]Joy MT, Vrbova G, Dhoot GK, Anderson PN (2015) Sulf1 and Sulf2 expression in the nervous system and its role in limiting neurite outgrowth in vitro. Exp Neurol 263, 150– 160. 25448158
  30. [30]Huynh MB, Villares J, Diaz JE, Christiaans S, Carpentier G, Ouidja MO, Sissoeff L, Raisman-Vozari R, Papy-Garcia D (2012) Glycosaminoglycans from aged human hippocampus have altered capacities to regulate trophic factors activities but not Abeta42 peptide toxicity. Neurobiol Aging 33, 1005 e 1011– 1022. 22035591
  31. [31]Petersen RC, Kokmen E, Tangalos E, Ivnik RJ, Kurland LT (1990) Mayo clinic Alzheimer’s disease patient registry. Aging (Milano) 2, 408– 415. 2094381
  32. [32]Hunderfund AL, Roberts RO, Slusser TC, Leibson CL, Geda YE, Ivnik RJ, Tangalos EG, Petersen RC (2006) Mortality in amnestic mild cognitive impairment: A prospective community study. Neurology 67, 1764– 1768. 17130407
  33. [33]Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, Rocca WA (2008) The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58– 69. 18259084 PMC2821441
  34. [34]McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939– 944. 6610841
  35. [35]McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7, 263– 269. 21514250 PMC3312024
  36. [40]Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41, 479– 486. 2011243
  37. [41](1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 18, S1– 2. 9330978
  38. [43]Powers JM (1997) Diagnostic criteria for the neuropathologic assessment of Alzheimer’s disease. Neurobiol Aging 18, S53– 54. 9330986
  39. [44]Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62, 1087– 1095. 14656067
  40. [45]Dickson DW, Rogers J (1992) Neuroimmunology of Alzheimer’s disease: A conference report. Neurobiol Aging 13, 793– 798. 1491745
  41. [46]Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR (2006) SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 130, 2130– 2144. 16762634
  42. [47]Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS, Roberts LR (2008) Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47, 1211– 1222. 18318435 PMC2536494
  43. [48]Shire A, Lomberk G, Lai JP, Zou H, Tsuchiya N, Aderca I, Moser CD, Gulaid KH, Oseini A, Hu C, Warsame O, Jenkins RB, Roberts LR (2015) Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis. Med Epigenet 3, 1– 18. 26236329 PMC4520440
  44. [49]Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR (2010) Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 30, 1522– 1528. 21040406 PMC3042145
  45. [50]Hosono-Fukao T, Ohtake-Niimi S, Hoshino H, Britschgi M, Akatsu H, Hossain MM, Nishitsuji K, van Kuppevelt TH, Kimata K, Michikawa M, Wyss-Coray T, Uchimura K (2012) Heparan sulfate subdomains that are degraded by Sulf accumulate in cerebral amyloid ss plaques of Alzheimer’s disease: Evidence from mouse models and patients. Am J Pathol 180, 2056– 2067. 22429964
  46. [51]Perry G, Siedlak SL, Richey P, Kawai M, Cras P, Kalaria RN, Galloway PG, Scardina JM, Cordell B, Greenberg BD, Ledbetter SR, Gambetti P (1991) Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer’s disease. J Neurosci 11, 3679– 3683. 1941102 PMC6575552
  47. [52]Siedlak SL, Cras P, Kawai M, Richey P, Perry G (1991) Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease. J Histochem Cytochem 39, 899– 904. 1865106
  48. [53]van Horssen J, Kleinnijenhuis J, Maass CN, Rensink AA, Otte-Holler I, David G, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM (2002) Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol Aging 23, 537– 545. 12009503
  49. [54]van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM (2003) Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-related disorders. Lancet Neurol 2, 482– 492. 12878436
  50. [55]O’Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, Kalimo H, Lindahl U, Lannfelt L, Zhang X (2008) Heparan sulfate accumulation with Abeta deposits in Alzheimer’s disease and Tg2576 mice is contributed by glial cells. Brain Pathol 18, 548– 561. 18422760 PMC2856073
  51. [56]Bruinsma IB, te Riet L, Gevers T, ten Dam GB, van Kuppevelt TH, David G, Kusters B, de Waal RM, Verbeek MM (2010) Sulfation of heparan sulfate associated with amyloid-beta plaques in patients with Alzheimer’s disease. Acta Neuropathol 119, 211– 220. 19636575
  52. [57]Small DH, Nurcombe V, Moir R, Michaelson S, Monard D, Beyreuther K, Masters CL (1992) Association and release of the amyloid protein precursor of Alzheimer’s disease from chick brain extracellular matrix. J Neurosci 12, 4143– 4150. 1279136 PMC6576018
  53. [58]Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, Masters CL (1994) A heparin-binding domain in the amyloid protein precursor of Alzheimer’s disease is involved in the regulation of neurite outgrowth. J Neurosci 14, 2117– 2127. 8158260 PMC6577125
  54. [59]Small DH, Williamson T, Reed G, Clarris H, Beyreuther K, Masters CL, Nurcombe V (1996) The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer’s disease. Ann N Y Acad Sci 777, 316– 321. 8624106
  55. [60]Timmer NM, Schirris TJ, Bruinsma IB, Otte-Holler I, van Kuppevelt TH, de Waal RM, Verbeek MM (2010) Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Abeta40 (DAbeta(1-40)) are modulated by sulfate moieties of heparin. Neurosci Res 66, 380– 389. 20036698
  56. [61]Valle-Delgado JJ, Alfonso-Prieto M, de Groot NS, Ventura S, Samitier J, Rovira C, Fernandez-Busquets X (2010) Modulation of Abeta42 fibrillogenesis by glycosaminoglycan structure. FASEB J 24, 4250– 4261. 20585030
  57. [62]Shimizu H, Ghazizadeh M, Sato S, Oguro T, Kawanami O (2009) Interaction between beta-amyloid protein and heparan sulfate proteoglycans from the cerebral capillary baent membrane in Alzheimer’s disease. J Clin Neurosci 16, 277– 282 sem. 19091577
  58. [63]Iivonen S, Helisalmi S, Mannermaa A, Alafuzoff I, Lehtovirta M, Soininen H, Hiltunen M (2003) Heparan sulfate proteoglycan 2 polymorphism in Alzheimer’s disease and correlation with neuropathology. Neurosci Lett 352, 146– 150. 14625044
  59. [64]Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A, Grenader T, Wertman E, Abramsky O (2004) An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 128B, 123– 125. 15211644
  60. [65]Kalus I, Salmen B, Viebahn C, von Figura K, Schmitz D, D’Hooge R, Dierks T (2009) Differential involvement of the extracellular 6-O-endosulfatases Sulf1 and Sulf2 in brain development and neuronal and behavioural plasticity. J Cell Mol Med 13, 4505– 4521. 20394677 PMC4515066
  61. [66]Nagamine S, Tamba M, Ishimine H, Araki K, Shiomi K, Okada T, Ohto T, Kunita S, Takahashi S, Wismans RG, van Kuppevelt TH, Masu M, Keino-Masu K (2012) Organ-specific sulfation patterns of heparan sulfate generated by extracellular sulfatases Sulf1 and Sulf2 in mice. J Biol Chem 287, 9579– 9590. 22298771 PMC3308746
  62. [67]Kalus I, Rohn S, Puvirajesinghe TM, Guimond SE, Eyckerman-Kolln PJ, Ten Dam G, van Kuppevelt TH, Turnbull JE, Dierks T (2015) Sulf1 and Sulf2 differentially modulate heparan sulfate proteoglycan sulfation during postnatal cerebellum development: Evidence for neuroprotective and neurite outgrowth promoting functions. PLoS One 10, e0139853. 26448642 PMC4598108

Cited by

Sorted by citations

Authors
Roberts, R. O., Kang, Y. N., Hu, C., Moser, C. D., Wang, S., Moore, M. J., Graham, R. P., Lai, J.-P., Petersen, R. C., & Roberts, L. R.
Affiliations
  • Mayo Clinic (US)
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Corresponding author
Roberts, Rosebud O.
ORCID
Venue
Journal of Alzheimer's Disease Reports
Publisher
SAGE Publications
Published
2017-09-19
Volume
1
Issue
1
Pages
115-124
ISSN
2542-4823 (ISSN-L)
DOI
10.3233/adr-170028
PMC
PMC6052874
OpenAlex
W2756722491
Cited by
19
References
2
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 1 · 2018: 1
FWCI
0.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Alzheimer s Disease Reports (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Mayo Clinic
  • National Institutes of Health (UL1TR000135)
  • National Institute on Aging (U01AG006786, K01AG028573, P50AG016574)
  • National Cancer Institute (N01 CA015083, R01CA165076, P30CA015083)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK084567)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, SULF2, SULF1, sulfatide, brain protein expression, hippocampus, cornu ammonis, parahippocampal gyrus, frontal lobe, neuropathology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review